Clinical Trial Update: An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis [Phase 3]

View source ↗

Summary

An open-label, nonrandomized multicenter extension study to assess the long-term safety and efficacy of Pegcetacoplan in participants with C3 glomerulopathy or …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• C3 Glomerulopathy
• Immune Complex Membranoproliferative Glomerulonephritis

Drugs mentioned

• EMPAVELI (pegcetacoplan)

Snippet

Sponsor: Apellis Pharmaceuticals, Inc. | Conditions: C3G, IC-MPGN | Phase 3 | Status: ACTIVE_NOT_RECRUITING